Clinical Trial Update: Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock

View source ↗

Summary

The completed clinical trial evaluated hypoxia-inducible factor 1 alpha as a biomarker in septic shock, assessing its potential utility in sepsis management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Snippet

Sponsor: University of Florida | Conditions: Sepsis | Status: COMPLETED